<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25086">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02780180</url>
  </required_header>
  <id_info>
    <org_study_id>QUID-HF_V1.0_20160106</org_study_id>
    <nct_id>NCT02780180</nct_id>
  </id_info>
  <brief_title>QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF</brief_title>
  <acronym>QUID-HF</acronym>
  <official_title>A Phase II Randomized, Placebo Controlled, Double-blind, Multi-centre Study to Assess Safety and Efficacy of Incremental Doses of QGC001 in Patients Upon Discharge From Hospital Admission for Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Quantum Genomics SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Quantum Genomics SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart Failure (HF) a common clinical condition characterized by either by a heart that does
      not pump sufficiently or becomes stiff. A variety of mechanisms contribute to progressive
      cardiac remodeling and dysfunction.

      A new therapeutic approaches by preventing activation of the brain neuromodulatory pathway,
      may lead to improve HF.

      QCG001 is a prodrug of EC33, a aminopeptidase A (APA) inhibitor. QCG001 has been shown to be
      an antihypertensive agent in animal models.

      This study investigates the safety and efficacy of QGC001 in HF patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite advances in care, prognosis remains poor once overt Heart Failure (HF) has
      developed. HF is a common clinical condition characterized by either by a heart that does
      not pump sufficiently or becomes stiff and it is associates with higher incidences of
      patient illness and death in both case. A variety of mechanisms contribute to progressive
      cardiac remodeling and dysfunction.

      A new therapeutic approaches by preventing activation of the brain neuromodulatory pathway,
      may lead to improve HF.

      QCG001 is a prodrug of EC33, a specific and selective of the aminopeptidase A (APA)
      inhibitor. QCG001 has been shown to be an antihypertensive agent in animal models.

      This study investigates the safety and efficacy of QGC001 up-titrated form 50mg twice daily
      to a maximum of 500 mg twice daily, on patients with worsening chronic HF during 28 days and
      7 days after discontinuation (day 35).

      6 European countries are involved in this study (France, Netherlands, Germany, Norway,
      Poland and United Kingdom) including 10 investigational hospitals. Patients would be
      followed during 35 days and inclusion period lasts 10 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative decrease in NT-proBNP</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage of subjects with a relative decrease in NT-proBNP of more than 30% from Baseline to day 28.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure change</measure>
    <time_frame>28 days</time_frame>
    <description>Blood pressure changes at each visit (D7, D14, D21, D28), compared to the Baseline measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood biochemistry</measure>
    <time_frame>35 days</time_frame>
    <description>blood biochemistry at D7, D14, D21, D28 and D35.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary biochemistry</measure>
    <time_frame>35 days</time_frame>
    <description>electrolytes, urinary osmolarity at D7, D14, D21, D28 and D35.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of NT-proBNP</measure>
    <time_frame>35 days</time_frame>
    <description>Changes in central lab values of NT-proBNP at D7, D14, D21, D28 and D35.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of BNP</measure>
    <time_frame>35 days</time_frame>
    <description>Changes in central lab values of BNP at D7, D14, D21, D28 and D35.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of selected biomarker levels</measure>
    <time_frame>28 days</time_frame>
    <description>Changes in central lab values from baseline in selected biomarker levels (copeptin, apelin, PRA and others biomarkers involved in the pathophysiology of the disease, which will be decided later) at Day 7, Day 14, Day 21, Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life Minnesota Living with Heart Failure Score</measure>
    <time_frame>28 days</time_frame>
    <description>Quality of life Minnesota Living with Heart Failure Score and D0 and Day 28</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>QGC001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QGC001 from 50mg to 500mg capsule twice daily, for 28 days, oral use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, capsule twice daily, for 28 days, oral use</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QGC001</intervention_name>
    <arm_group_label>QGC001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lactose capsule manufactured to mimic QGC001 50 mg and 250 mg</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A signed and dated informed consent form prior to any study procedure

          -  Adult male subjects and female subjects without childbearing potential ≤ 80 years

          -  Clinical diagnosis of WHF, who were New York Heart Association (NYHA) class II - III
             at least 3 months prior to emergency presentation to hospital.

          -  Eligible subjects must be enrolled short before discharge or within 8 days after
             discharge from an episode of decompensated HF (index event) defined as

               1. an overnight stay in a hospital, emergency department, or medical observation
                  facility with the capability of treating with intravenous medications and
                  observing HF patients, or

               2. an unscheduled outpatient visit to a HF management centre, where parenteral
                  therapy is required for HF stabilization.

          -  Documented left ventricular ejection fraction (LVEF) 40% measured by any modality
             within the previous 6 months in the subject's medical history

          -  Subjects must also have at least one local measurement of BNP level ≥ 400 pg/mL or
             NT-proBNP level ≥1600 pg/mL (preferred assay, local lab) at any time during the index
             hospitalization or before randomisation.

          -  eGFR &gt; 60 mL/min/1.73 m2 (MDRD) at screening

          -  No decrease in eGFR greater than 20% from admission to the index hospitalisation and
             up to the randomisation day.

          -  Serum potassium 5.0 mmol/L at screening

          -  Systolic blood pressure 120 mmHg (average of 3 consecutive measurements)

          -  Prescribed to optimal pharmacologic therapy per ESC guidelines for the diagnosis and
             treatment of acute and chronic heart failure 2012&quot;, or based on the updated current
             clinical practice, unless contra-indicated or not-tolerated, and on a stable dose
             (e.g., recommended not more than double or decrease in dosage) for at least 30 days
             prior to enrolment.

          -  Taking oral loop diuretics at doses &lt; 250 mg furosemide daily (or equivalent)

        Exclusion Criteria:

          -  Age &gt; 80 years

          -  BMI &gt; 35kg.m-2

          -  Patients who require the use of HF IV therapy or oral furosemide &gt; 250 mg (or
             equivalent) at any time during the 48 hours immediately before randomisation.

          -  Patients with unstable angina, myocardial infarction, PTCA, coronary artery bypass
             graft, cerebral vascular accident, or transient ischemic attack within previous 3
             months (90 days) before enrolment.

          -  Patients whose primary cause of heart failure is mitral or aortic valve disease or
             congenital heart disease or hypertrophic obstructive cardiomyopathy or infiltrative
             cardiomyopathy (e.g. amyloidosis, sarcoidosis) or myocarditis.

          -  Patients with permanent atrial fibrillation (AF) (per &quot;ACC/AHA/ESC 2006 guidelines
             for the management of patients with AF&quot;) within 3 months (90days) prior to enrolment

          -  Patients scheduled for Pacemaker (including ICD, CRT), Angioplasty, CABG or LVAD
             within the next 3 months

          -  Patients with documented chronic obstructive lung disease.

          -  eGFR &lt; 60 mL/min/1.73 m2 (MDRD) at screening

          -  Decrease in eGFR greater than 20% from admission to the index hospitalisation and up
             to the randomisation day

          -  Serum potassium &gt; 5.0 mmol/L at screening

          -  Systolic blood pressure &lt; 120 mmHg or with signs or symptoms of hypotension

          -  Symptomatic hypotension or orthostatic hypotension defined by a decrease of more than
             30 mm Hg in the standing vs. sitting position at screening and at T0 of the D0
             (before having taken the study medication)

          -  Insulin-requiring diabetic patients (including type 1 Diabetes)

          -  HbA1c ≥ 10% at screening visit

          -  History of angioneurotic edema

          -  Patients with a life expectancy of less than 12 months per physician judgment

          -  Patients involved in any clinical study

          -  Patients who take an investigational or non-approved treatment

          -  Women of childbearing potential who are or might be pregnant at the time of the study
             (method of assessment upon physician's discretion)

          -  Patients with a prior cardiac transplant or patients currently on the list for
             cardiac transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faiez Zannad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre d'investigation clinique CHU-Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cecile Dollinger</last_name>
    <phone>0383501922</phone>
    <phone_ext>33</phone_ext>
    <email>cdollinger@eddh.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stéphanie Grojean</last_name>
    <phone>0383501921</phone>
    <phone_ext>33</phone_ext>
    <email>sgrojean@eddh.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Louis Pradel</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Sebbag, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Laurent Sebbag, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Laennec</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Noel Trochu, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Noel Trochu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice Bauer, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Fabrice Bauer, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Bauersachs, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Johan Bauersachs, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Innere Medizin III</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Boehm, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Michael Boehm, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriaan Voors</last_name>
    </contact>
    <investigator>
      <last_name>Adriaan Voors, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <zip>PO 5800</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Peter Brunner-La Rocca, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Hans-Peter Brunner-La Rocca</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Dickstein, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Kenneth Dickstein, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Military Hospital</name>
      <address>
        <city>Wroclaw</city>
        <zip>50981</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Szachniewicz, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Joanna Szachniewicz, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chim Lang, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Chim Lang, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 28, 2017</lastchanged_date>
  <firstreceived_date>May 17, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aminopeptidase A inhibitor</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Up-titration</keyword>
  <keyword>Dose-Response Relationship, Drug</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Patient Safety</keyword>
  <keyword>Treatment Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant date would be available only by the center via eCRF</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
